Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

When could it reach patients?
Submitted to the FDA and could be approved this year.
Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related...
How will a new drug fare in a 4,000-patient, four-year study?
First-ever SGLT-2/DPP-4 inhibitor drug, will this combination cut costs for patients?
How this “disease interception” strategy could transform our knowledge of type 1 diabetes.
How a major research study is challenging an outdated FDA restriction.
Sanofi and MannKind announce Afrezza's official US launch.
What happens when these two unique drugs are taken together?
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
Twitter summary: FDA approves Novo Nordisk’s chronic weight management drug Saxenda, another option to help treat #obesity On December 23, the FDA approved Novo Nordisk’...
Twitter Summary: Lilly’s Trulicity, a once-weekly GLP-1 agonist available in US, has now been approved in Europe On November 25, Eli Lilly’s Trulicity (dulaglutide) was...
ClinicalTrials.gov Identifier: NCT00920582 This study is currently recruiting patients recently diagnosed with type 1 diabetes to investigate the efficacy of teplizumab...
Twitter summary: JAMA study shows that metformin is safest first-line therapy for type 2 diabetes – future GRADE study to show best second-line therapy The journal JAMA...
Twitter summary: @LillyDiabetes launches Trulicity in the US – first ready-to-use once-weekly GLP-1, available w/savings program for commercially insured On November 10...
When one is better than two – how combining two effective diabetes drugs into a single pill can improve management.
Twitter summary: FDA approves Xigduo XR – first once-daily SGLT-2 inhibitor/metformin fixed dose combo in the US AstraZeneca recently announced that the FDA approved...
Twitter summary: Contrave launched in the US w/ weight support program + savings/loyalty programs offer new option for patients Two healthcare companies, Orexigen and...
Twitter summary: Roche’s Lucentis granted “priority review” from FDA – decision by Feb. 2015, potentially 1 st ever eye medicine for diabetic retinopathy Roche recently...
Twitter Summary: @LillyPad receives EU approval for Humalog 200 units/ml Kwikpen – 600 units of insulin in a 3 ml pen, hopeful US resubmission late 2014 Eli Lilly...

Pages